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Background: Circulating free fatty acids are often elevated in patients with type 2 diabetes (T2D) and obese
individuals. Chronic exposure to high levels of saturated fatty acids has detrimental effects on islet function and
insulin secretion. Altered gene expression and epigenetics may contribute to T2D and obesity. However, there is
limited information on whether fatty acids alter the genome-wide transcriptome profile in conjunction with DNA
methylation patterns in human pancreatic islets. To dissect the molecular mechanisms linking lipotoxicity to
impaired insulin secretion, we investigated the effects of a 48 h palmitate treatment in vitro on genome-wide
mRNA expression and DNA methylation patterns in human pancreatic islets.
Methods: Genome-wide mRNA expression was analyzed using Affymetrix GeneChip® Human Gene 1.0 ST whole
transcript-based array (n = 13) and genome-wide DNA methylation was analyzed using Infinium HumanMethylation450K
BeadChip (n = 13) in human pancreatic islets exposed to palmitate or control media for 48 h. A non-parametric paired
Wilcoxon statistical test was used to analyze mRNA expression. Apoptosis was measured using Apo-ONE® Homogeneous
Caspase-3/7 Assay (n = 4).
Results: While glucose-stimulated insulin secretion was decreased, there was no significant effect on apoptosis in
human islets exposed to palmitate. We identified 1,860 differentially expressed genes in palmitate-treated human islets.
These include candidate genes for T2D, such as TCF7L2, GLIS3, HNF1B and SLC30A8. Additionally, genes in glycolysis/
gluconeogenesis, pyruvate metabolism, fatty acid metabolism, glutathione metabolism and one carbon pool by folate
were differentially expressed in palmitate-treated human islets. Palmitate treatment altered the global DNA methylation
level and DNA methylation levels of CpG island shelves and shores, 5′UTR, 3′UTR and gene body regions in human islets.
Moreover, 290 genes with differential expression had a corresponding change in DNA methylation, for example, TCF7L2
and GLIS3. Importantly, out of the genes differentially expressed due to palmitate treatment in human islets, 67 were also
associated with BMI and 37 were differentially expressed in islets from T2D patients.
Conclusion: Our study demonstrates that palmitate treatment of human pancreatic islets gives rise to epigenetic
modifications that together with altered gene expression may contribute to impaired insulin secretion and T2D.
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Table 1 Characteristics of human pancreatic donors
included in the mRNA expression array analysis
n (male/female) 13 (7/6)
Age (years) 55 ± 14
BMI (kg/m2) 25.5 ± 4.3
HbA1c* (%) 5.6 ± 0.9
HbA1c* (mmol/mol) 47.6 ± 9.2
Data are expressed as mean ± SD. BMI, Body Mass Index.
*Data available for eight donors (five males and three females).
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The risk of developing type 2 diabetes (T2D) is influenced
by both genetic and environmental factors. While
genome-wide association studies (GWAS) have identified
more than 60 single nucleotide polymorphisms (SNPs) as-
sociated with an increased risk for T2D [1,2], obesity,
physical inactivity and ageing represent non-genetic risk
factors for the disease. Recent studies suggest that epigen-
etic factors, such as DNA methylation, play a role in the
pathogenesis of T2D [3-11]. Nevertheless, genome-wide
human epigenetic studies linking altered DNA methyla-
tion to diabetes remain scarce. In mammalian cells DNA
methylation mainly occurs at the cytosine of CpG dinucle-
otides. Methylated CpG sites can alter transcriptional ac-
tivity by interfering with binding of transcription factors
in promoter regions or by recruiting methyl binding pro-
teins which in turn may recruit histone deacethylases and
transcriptional co-repressors [3]. Increased DNA methyla-
tion of beta-cell specific genes, such as PDX-1 and INS,
correlates negatively with the expression of respective
genes in pancreatic islets from T2D patients [4,5].
Plasma levels of free fatty acids are often elevated in T2D
patients and in obese individuals [12,13]. Chronic exposure
to high levels of fatty acids has negative effects on beta-cell
function [12,13]. The severity of this effect depends on the
length and saturation of fatty acids. Long chain saturated
fatty acids, for example, palmitate and stearate, are report-
edly more cytotoxic than the long chain unsaturated fatty
acid oleate [14-16], and long term treatment (≥48 h) with
palmitate reduces glucose-stimulated insulin secretion in
rodent islets and clonal beta-cells [17,18]. Moreover, pro-
longed exposure to non-esterified fatty acids in vivo also
resulted in impaired islets function and decreased glucose-
stimulated insulin secretion in humans [19,20]. Addition-
ally, transcriptome analyses of clonal beta-cells revealed
differences in the gene expression pattern in cells treated
with high palmitate concentrations. Specifically, palmitate
exposure altered the expression of genes with a role in fatty
acid metabolism and steroid biosynthesis [21,22]. In
clonal beta-cells, palmitate exposure also altered his-
tone modifications [22]. As most of the cell types in pan-
creatic islets affect whole body energy homeostasis [23], it
is essential to also study the impact of fatty acids on in-
tact human islets. However, while some studies have ana-
lyzed expression of specific genes in human islets exposed
to palmitate [24-27], to our knowledge no previous study
has analyzed the genome-wide expression profile in
palmitate-treated human islets of more than five human
donors [28,29]. Moreover, whether the genome-wide
DNA methylation pattern is affected by fatty acids in hu-
man islets remains unknown.
The aim of this study was therefore to investigate if
treatment with palmitate for 48 h affects genome-wide
mRNA expression and DNA methylation patterns inhuman pancreatic islets and, consequently influences
glucose-stimulated insulin secretion and/or apoptosis.
To validate our in vitro findings, we related genome-
wide gene expression in human islets to BMI in non-
diabetic individuals and to T2D in a case-control cohort.
Methods
Human pancreatic islets
Pancreatic islets from 13 donors were included in the
genome-wide RNA and DNA methylation array analyses.
While pancreatic islets from eight donors were included
in both the mRNA array analysis and the DNA methyla-
tion array analysis, pancreatic islets from five donors
were unique for each array (Table 1 and Additional file 1:
Table S1). The impact of body mass index (BMI) on gene
expression was studied in pancreatic islets from 87 non-
diabetic donors (53 males and 34 females, BMI ranged be-
tween 17.6 to 40.1 kg/m2, mean BMI = 25.8 ± 3.4 kg/m2,
age = 56.7 ± 10.5 years). The impact of T2D on gene ex-
pression was studied in pancreatic islets from 15 donors
(10 males and 5 females, age = 59.5 ± 10.7 years and mean
BMI = 28.3 ± 4.7 kg/m2) diagnosed with T2D and 34 non-
diabetic donors (22 males and 12 females, age = 56.0 ±
9.0 years and mean BMI = 28.3 ± 4.7 kg/m2) with an
HbA1c below 6.0%. Informed consent for organ donation
for medical research was obtained from pancreatic donors
or their relatives in accordance with the approval by the
regional ethics committee in Lund, Sweden (Dnr 173/
2007). This study was performed in agreement with the
Helsinki Declaration.
Human pancreatic islets were prepared by collagenase
digestion and density gradient purification. The islet
purity was 80% ± 2.5%, as assessed by the ratio of expres-
sion of islet (INS, GCG, and SST) and non-islet specific
(AMY2A, PNLIP, CTRC) genes.
Preparation of medium containing palmitate
First, a stock solution of 10 mM palmitate and 10% fatty
acid free BSA was created. A total of 128 mg palmitate
was dissolved in 50 ml 99% ethanol and then 60 μl 10 M
NaOH was added. The solution was vacuum-dried and
then resolved in 25 ml H2O during heating. Next, 6 g of
fatty acid free BSA was dissolved in 24 ml H2O and then
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lution. The stock solution was then diluted to a final
concentration of 1 mM palmitate and 1 weight % BSA
(corresponding to 0.15 mM BSA) in the CMRL 1066
medium (ICN Biomedicals, Costa Mesa, CA, USA) sup-
plemented with 10 mM nicotinamide (Sigma-Aldrich,
Sweden, Stockholm), 10 mM HEPES buffer (GIBCO,
BRL, Gaithersburg, MD, USA), 0.25 μg/ml fungizone
(GIBCO), 50 μg/ml gentamicin, 2 mM L-glutamine
(GIBCO), 10 μg/ml Ciprofloxacin (Bayer Healthcare,
Leverkusen, Germany), 10% (v/v) heat-inactivated hu-
man serum and 5.56 mM glucose. The molar (mmol/l)
ratio of palmitate/BSA concentrations was 6.6:1 in the
culture medium.
Palmitate treatment
To study the impact of palmitate-induced lipotoxicity on
human islets, approximately 1,000 islets from each donor
(n = 13) were cultured for 48 h in CMRL 1066 medium
(including 5.56 mM glucose) either with (lipotox) or with-
out (control) 1 mM palmitate conjugated with 1% BSA
(corresponding to 0.15 mM BSA) (Figure 1a). The same
treatment time and palmitate/BSA ratio have been
used in previous studies examining the impact of lipo-
toxicity on islet function and was therefore selected in
the present study [22,30]. Circulating non-esterified
fatty acid levels have been reported to range between
0.59 to 0.83 mM for overweight, non-diabetic individ-
uals (BMI approximately 26 kg/m2) and between 0.69
to 0.975 mM for overweight, diabetic individuals (BMI
of approximately 29 kg/m2) [31]. The 1 mM palmitate
used in the current study, which is close to the upper
limit of the reference range, mimics the levels reported
in overweight/obese individuals with diabetes. After
48 h DNA and RNA were extracted, glucose-stimulated
insulin secretion was analyzed and/or apoptosis assays
were performed.
RNA and DNA isolation
DNA and RNA were extracted from the human pancreatic
islets using the AllPrep DNA/RNA kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions.
RNA quantity and quality were assessed by Nanodrop
(Nanodrop, Wilmington, DE, USA). The 260/280 ratios of
all samples were between 1.98 and 2.16. The integrity and
quality of the RNA was assessed using the Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA). All RNA
integrity number (RIN) values were ≥7.4.
Microarray mRNA expression analysis
The Affymetrix GeneChip® Human Gene 1.0 ST whole
transcript-based array (Affymetrix, Santa Clara, CA, USA)
covering 28,869 genes was used to analyze mRNA ex-
pression (Figure 1b) in pancreatic islets from 13 humandonors (Table 1) exposed to palmitate or control condi-
tions (in total 26 samples) and in pancreatic islets from 87
non-diabetic donors as well as from diabetic and non-
diabetic donors, according to the manufacturer’s recom-
mendations. The Oligo package from Bioconductor was
used to compute Robust Multichip Average expression
measures [32].
Genome-wide DNA methylation analysis
A total of 500 ng genomic DNA from human pancreatic
islets of 13 donors (Additional file 1: Table S1) exposed
to palmitate or control conditions (in total 26 samples)
was bisulfite-converted with the EZ DNA methylation
kit (Zymo Research Corporation, Irvine, CA, USA).
DNA methylation was analyzed by using the Infinium
HumanMethylation450K BeadChip (Illumina, San Diego,
CA, USA) which contains 485,577 probes and covers
99% of all RefSeq genes [33]. Bisulfite converted DNA
was used to analyze DNA methylation with the Infi-
nium® assay according to the standard Infinium HD
Assay Methylation Protocol (Part # 15019519, Illumina).
The Infinium HumanMethylation450K BeadChips were
then imaged with the Illumina iScan. The raw methyla-
tion score for each CpG site, which is represented as
β-value, was calculated using the GenomeStudio® methy-
lation module software. The β-values were calculated as
(β = intensity of the methylated allele (M)/(intensity of
the Unmethylated allele (U) + intensity of the Methylated
allele (M) + 100)). All samples passed GenomeStudio®
quality control steps based on built-in control probes for
staining, hybridization, extension and specificity, and dis-
played high quality bisulfite conversion efficiency with an
intensity signal above 4,000 [34]. Probes were filtered away
from further analysis based on a mean detection P-value
>0.01. After quality control analysis, DNA methylation
data were obtained for 483,844 probes. β-values were then
converted to M-values (M = log2 (β/(1 - β))) for further
bioinformatic and statistical analyses of the methylation
data [35]. Background and quantile normalization was
performed using the lumi package from Bioconductor
[36]. Background correction was performed by subtracting
the median M-value of the 600 built-in negative controls
and methylation data were further normalized using quan-
tile normalization [37]. ComBat was used to adjust for
batch effects between arrays [38]. A linear regression model
was used to identify differences in DNA methylation
between control and palmitate-treated islets in a paired
fashion as described elsewhere [39]. As β-values are bio-
logically easier to interpret, M-values were reconverted to
β-values when describing the DNA methylation results.
The DNA methylation probes on the Infinium Human-
Methylation450K BeadChip have been annotated to differ-
ent genomic regions depending on their location in
relation to a gene or a CpG island [33].
Figure 1 Study design and work flow. Study design for the lipotoxicity study in human pancreatic islets is presented in panel a Work flow for
the analysis of mRNA expression data in combination with DNA methylation data in human pancreatic islets exposed to palmitate is presented
in panel b.
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Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway analysis of expression data was performed
with the online tool WebGestalt [40,41] (accessed 27
March 2012 and 12 February 2014). For the pathway
analysis of mRNA expression data, Affymetrix probe
IDs were used to identify unique genes and AffymetrixGeneChip® Human Gene 1.0 ST genes were used as
background in this analysis. For the pathway analysis
of the DNA methylation data, the gene symbol was
used to identify unique genes and the human genome
was used as background in this analysis. The Benjamini
and Hochberg method was used to correct P-values for
multiple testing.
Figure 2 Impact of palmitate treatment on insulin secretion
and apoptosis in human pancreatic islets. a) Glucose-stimulated
insulin secretion represented as fold change of insulin secretion
(insulin secretion at high glucose levels/insulin secretion at low
glucose levels) from human islets (n = 9) exposed to palmitate or
control treatment for 48 h. A Wilcoxon one-tailed test was used.
*P ≤0.05. b) Combined activity of Caspase-3/-7 as a measure of
apoptosis in human islets (n = 4) exposed to palmitate or control
treatment for 48 h. A Wilcoxon test was performed.
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Glucose-stimulated insulin secretion was analyzed in con-
trol and palmitate-treated human islets from nine donors.
After 48 h culture in control or palmitate-containing
medium, 10 replicates of 10 human islets per culture con-
dition (control and palmitate-treated) and donor were
pre-incubated in HEPES-balanced salt solution (HBSS)
containing (in mM) 114 NaCl, 4.7 KCl, 1.2 KH2PO4, 1.16
MgSO4, 20 HEPES, 25.5 NaHCO3, 2.5 CaCl2 at pH 7.2
with 0.575 BSA and 3.3 mM glucose (1.65 mM glucose for
one sample) for 1 h at 37°C. Thereafter, for each donor,
glucose was added to five of the replicates to a final con-
centration of 16.7 mM glucose (15.05 mM glucose for one
sample) to study glucose-stimulated insulin secretion and
the other five replicates were kept in 3.3 mM glucose
to study basal insulin secretion and the incubation was
continued for one more hour. The supernatant was im-
mediately removed and the insulin concentration in the
medium was measured by radioimmunoassay (RIA)
(Millipore, Uppsala, Sweden).
Assessment of apoptosis in human pancreatic islets
Apoptosis was measured in islets from four human do-
nors with the Apo-ONE® Homogeneous Caspase-3/7
Assay (Promega, Madison, WI, USA) as described else-
where [42]. The assay contains proflourescent rhodamin
110 (Z-DEVD-R110) which serves as a substrate for both
Caspase-3 and -7. Upon lysis of cells, the available Cas-
pase -3/-7 in the sample will cleave Z-DEVD-R110 to
fluorescent rhodamine 110, which is then measured.
Subsequently, the assay measures the combined activity of
Caspase-3 and -7. After 48 h incubation in control or
palmitate medium, triplicates of 20 human pancreatic is-
lets each were handpicked from each culture condition,
washed and transferred to a plate containing HBSS. After
1.5 h, fluorescence was measured with a Tecan Infinite
M200pro plate reader (Tecan Group Ltd., Männedorf,
Switzerland) to determine the Caspase-3/7 activity.
Statistics
A non-parametric paired test (Wilcoxon) was used to
identify differences in mRNA expression between con-
trol and palmitate-treated human islets. A False Discov-
ery Rate (FDR) analysis was performed to correct for
multiple testing in the mRNA expression data. Genes
exhibiting differential expression with a FDR below 5%
(q <0.05) were considered significant. To find associa-
tions between BMI and gene expression in human is-
lets, a linear regression model was used including age,
gender, HbA1c, islet purity and days of culture as co-
variates. To identify differences in gene expression be-
tween T2D and non-diabetic islets a linear regression
model was used including gender, BMI, age, islet pur-
ity and days of culture as covariates. Data are presentedas mean ± standard error of mean (sem), unless stated
otherwise.Results
Impaired insulin secretion in human islets exposed
to palmitate
To investigate the physiological response to 1 mM palmi-
tate treatment for 48 h, we measured glucose-stimulated
insulin secretion in human islets cultured under control
(5.56 mM glucose) or lipotoxic (5.56 mM glucose and
1 mM palmitate) conditions. We found decreased glucose-
stimulated insulin secretion measured as fold change (insu-
lin secretion at high glucose levels/insulin secretion at
low glucose levels) in the palmitate-treated compared
with control-treated human islets (Figure 2a). We also
evaluated the effect of the palmitate treatment on apop-
tosis in human islets by measuring the combined activity
of Caspase-3 and -7. Palmitate treatment did not alter islet
cell apoptosis rates (P = 0.62, Figure 2b).
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human islets
To study the impact of palmitate-induced lipotoxicity on
gene expression in human islets, mRNA expression array
data were generated for pancreatic islets from 13 donors
cultured in control or lipotoxic conditions (Figure 1a). The
characteristics of these 13 donors are described in Table 1.
We identified 1,860 individual genes that were differentially
expressed in human islets exposed to palmitate compared
with the control condition after correction for multiple
testing using a FDR below 5% (q <0.05) (Additional file 2:
Table S2). Out of these 1,860 genes, 1,230 were down-
regulated and 630 genes were up-regulated due to palmi-
tate treatment. The work flow for the mRNA expression
data can be viewed in Figure 1b.
To test if genes in certain biological pathways were
enriched among the differentially expressed genes in
palmitate-treated human islets, KEGG pathway analyses
were performed using WebGestalt. Pathway analyses
were performed using either the list of all differentially
expressed genes (q <0.05) or by dividing the genes based
on down- or up-regulation in islets exposed to palmitate.
A selection of the enriched pathways (Padjusted <0.05)
can be found in Figure 3 and all enriched pathways of
possible relevance for lipotoxicity in human islets can be
found in Additional file 3: Table S3, Additional file 4:
Tables S4 and Additional file 5: Table S5. The metabolic
pathways was the top KEGG pathway with down-regulated
genes (Figure 3b and Additional file 4: Table S4) and it
includes several genes encoding proteins involved in
oxidative phosphorylation. Additionally, the glycolysis/
gluconeogenesis (Figures 3a, b, 4a and Additional file 3:
Table S3 and Additional file 4: Table S4), fatty acid metab-
olism, glutathione metabolism (Figures 3a, b, 4b and
Additional file 3: Table S3 and Additional file 4: Table
S4) and pyruvate metabolism (Figure 3b and Additional
file 4: Table S4) pathways were enriched in human islets
exposed to palmitate. Moreover, there was an enrich-
ment of genes involved in the insulin signaling pathway
(Figures 3a, 4c and Additional file 3: Table S3) and
the biosynthesis of unsaturated fatty acids pathway
(Figures 3a, 4d and Additional file 3: Table S3). Interest-
ingly, the “one carbon pool by folate” was also enriched in
the KEGG pathway analysis (Figure 3a, b and Additional
file 3: Table S3 and Additional file 4: Table S4).
We further examined if candidate genes associated
with either T2D, T2D-related traits or obesity in previ-
ous GWAS were differentially expressed in human islets
exposed to palmitate. Candidate gene lists were retrieved
using the online GWAS SNP library [43,44] (accessed
on 22 August 2012). Among these gene lists, we found
16 candidate genes for T2D out of a total of 86 genes
(Figure 5a and Additional file 6: Table S6), 13 T2D-
related trait genes out of a total of 76 (Figure 5b andAdditional file 7: Table S7) and 15 candidate genes for
obesity out of a total of 127 (Figure 5c and Additional
file 8: Table S8) that were differentially expressed
palmitate-treated islets. However, since some candidate
genes are associated with more than one trait, the differ-
entially expressed candidate genes correspond to 38
unique genes out of a total of 262 genes.
Impact of palmitate on DNA methylation in human islets
To estimate the global DNA methylation in human is-
lets, we calculated the average level of DNA methylation
for all analyzed CpG sites on the Infinium Human-
Methylation450K BeadChip array. The average level of
genome-wide DNA methylation was slightly, but signifi-
cantly, higher in palmitate-treated compared to control
islets (44.9 ± 0.8 vs. 43.9 ± 1.2, P = 0.002). The analyzed
DNA methylation sites on the array have been annotated
to different gene and CpG island regions [33]. The anno-
tated gene regions include TSS1500, TSS200, 5′UTR, 1st
exon, gene body, 3′UTR and intergenic regions. Annota-
tions were also made according to the location of the
DNA methylation sites in relation to CpG islands, as
previously defined [33]. The 2 kb sequences, directly up-
and downstream of CpG islands are called the northern
and southern shore, respectively. The 2 kb sequences
directly adjacent to the shores are called the northern
and southern shelves. DNA methylation sites outside the
CpG island regions are annotated as “open sea”. We
then tested if palmitate exposure affects the average level
of DNA methylation for any of these gene regions in hu-
man islets. We found an increase in average DNA
methylation in the palmitate-treated islets for all gene
and CpG island regions except TSS200, 1st Exon and
CpG islands (Figure 6 and Additional file 9: Table S9).
We next evaluated if palmitate also affects the level of
DNA methylation of individual CpG sites in human is-
lets. Genome-wide DNA methylation array data were
successfully generated for 483,844 sites in islets of 13
donors. Palmitate exposure changed the degree of DNA
methylation of 46,977 sites at P <0.05, which is almost
double the expected number with P <0.05 and signifi-
cantly more than expected based on a chi-squared test
(P <0.0001, Additional file 10: Table S10). However, no
individual methylation site had q <0.05 based on a FDR
analysis and the lowest P-value was 5.7 × 10−6. Out of
those, 4,690 sites had an absolute difference in DNA
methylation greater than 3% in palmitate-treated versus
control islets. This cut-off was set to increase the bio-
logical relevance of the results. Among the 4,690 sites
with an absolute difference in methylation greater than
3% and P <0.05, 4,561 sites displayed increased DNA
methylation due to palmitate treatment, corresponding
to 2,753 unique genes and 1,429 intergenic sites. More-
over, 129 sites showed decreased DNA methylation due
ab
c
Figure 3 Gene set analysis of differentially expressed genes in human islets exposed to palmitate. Results of KEGG pathway analysis
using a) all differentially expressed genes, b) down-regulated genes only and c) up-regulated genes only in human islets exposed to palmitate.
Numbers in brackets indicate the total number of genes in the corresponding pathway.
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94 unique genes, and 30 were intergenic sites. The fold
change for the 46,977 differentially methylated DNA
methylation sites (P <0.05), calculated as DNA methyla-
tion of palmitate-treated islets/DNA methylation of con-
trol treated islets, ranged from 0.54 to 1.84. This
corresponds to changes in DNA methylation from a 46%
decrease to an 84% increase.
Overlapping changes in mRNA expression and DNA
methylation in palmitate-treated human islets
Epigenetic modifications may regulate mRNA expression
[3-5] and we therefore tested if any of the genes thatexhibit differential mRNA expression also exhibit differen-
tial DNA methylation in islets exposed to palmitate. Sig-
nificant mRNA expression data (q <0.05) were merged
with DNA methylation sites with P <0.05 and an absolute
difference in DNA methylation ≥3%. We found 290 indi-
vidual genes with differential mRNA expression (q <0.05)
and a corresponding change in DNA methylation (in total,
371 DNA methylation sites) (Figure 1b and Additional file
11: Table S11). Out of these 290 genes, 213 had decreased
mRNA expression together with altered DNA methylation
(269 DNA methylation sites, whereof 264 sites had in-
creased and 5 sites had decreased DNA methylation) in
response to palmitate treatment. Additionally, 77 unique
Figure 4 Differential mRNA expression of genes in enriched KEGG pathways in palmitate-exposed human islets. a) Differentially down-
regulated genes in the glycolysis/gluconeogenesis pathway. b) Differentially expressed genes in the glutathione metabolism pathway. c) Differen-
tially expressed genes in the insulin signaling pathway. d) Differentially expressed genes in the biosynthesis of unsaturated fatty acids pathway.
All data are presented as mean ± sem. *q <0.05.
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tered DNA methylation (102 DNA methylation sites,
whereof 2 sites had decreased and 100 sites had increased
DNA methylation) (Figure 1b). Furthermore, for some of
the candidate genes for T2D, T2D related traits and obes-
ity identified by GWAS, we found both differential mRNA
expression and changes in DNA methylation in islets ex-
posed to palmitate, for example, TCF7L2 and GLIS3 show
decreased expression and increased DNA methylation
(Additional file 6: Table S6, Additional file 7: Table S7 and
Additional file 8: Table S8).
A KEGG pathway analysis was performed using Web-
Gestalt to test if genes in biological pathways found in
the mRNA expression pathway analysis (Additional file
3: Table S3, Additional file 4: Table S4 and Additional
file 5: Table S5) also were enriched among the differen-
tially methylated genes in palmitate-treated human islets.The pathway analysis was performed using a list of
all differentially methylated genes (P <0.05) (Additional
file 10: Table S10). All 17 pathways with enrichment for
both DNA methylation and gene expression are pre-
sented in Additional file 12: Figure S1 and Additional
file 13: Table S12.
The Infinium HumanMethylation450K BeadChip array
has been reported to have probes with possible cross re-
activity to other locations in the genome than their
intended match [45]. Importantly, none of our reported
probes with P <0.05 have a perfect match to other loca-
tions in the genome. Furthermore, only 13 probes have a
near-perfect match (Additional file 14: Table S13).
Impact of BMI and T2D on gene expression in human islets
Since it has been shown that T2D patients and obese
individuals have elevated levels of free fatty acids
ab
c
Figure 5 Impact of palmitate treatment on gene expression of candidate genes for T2D, related traits and obesity in human islets.
Differentially expressed candidate genes (q <0.05) for a) T2D, b) T2D related traits and c) obesity. Figures are divided into different expression
levels. All data are presented as mean ± sem. *q <0.05. T2D, type 2 diabetes.
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T2D also affect islet expression in the same direction as
any of the 1,860 genes that exhibit differential expression
in human islets exposed to lipotoxicity for 48 h in vitro.
The impact of BMI on expression of these 1,860 genes
was examined in human islets from 87 non-diabetic do-
nors with BMI spanning between 17.6 to 40.1 kg/m2. BMI
was associated with differential expression of 67 of the
1,860 genes (Additional file 15: Table S14). The impact of
T2D was examined in pancreatic islets from 15 donors
with T2D and 34 non-diabetic donors. We found 37 genes
differentially expressed (P <0.05) in islets from T2D versus
non-diabetic donors overlapping with the 1,860 genes in
the palmitate-exposed islets (Additional file 16: Table
S15). The data for three of these genes (that is, CDKN1A,
IL1RL2, TNFRSF10B) have been reported previously [48]
and are hence not reported here. The top 10 genes show-
ing differential expression in human islets due to both
palmitate exposure and T2D are presented in Figure 7.
Moreover, five genes, that is, RASGRP1, MIA2, CDKN1A,TNFRSF103 and RAB7L1, were present among both the
BMI- and T2D-associated genes.
Discussion
This study shows that palmitate exposure alters mRNA
expression genome-wide in human islets in parallel with
impaired insulin secretion, a defect often seen in T2D pa-
tients. Several genes with altered expression in palmitate-
treated human islets also exhibited differential expression
in islets from patients with T2D. We also demonstrate for
the first time that the genome-wide DNA methylation pat-
tern in human islets was affected by palmitate treatment.
Several genomic regions had significantly higher global
DNA methylation levels in the palmitate-treated islets
compared with control islets, although these differences
were generally small. This may be the result of the rela-
tively short treatment (48 h) and that DNA methylation
changes of a larger magnitude may require longer expos-
ure to hyperlipidemia, a condition seen in many T2D pa-
tients. Also, since T2D is known to be a polygenic disease,
Figure 6 Impact of palmitate treatment on global DNA
methylation in human islets. Average DNA methylation levels
of a) gene regions and b) CpG island regions in control and
lipotoxic treated human islets. All data are presented as mean
± sem. *q <0.05.
Figure 7 Top 10 genes showing differential expression in
human islets due to both palmitate exposure and T2D. a)
Relative mRNA expression of the top 10 significant genes, in human
islets exposed to control or palmitate treatment, overlapping with
differentially expressed genes in human islets from donors with or
without T2D. b) Relative mRNA expression of the top 10 significant
genes, in human islets from donors with or without T2D,
overlapping with differentially expressed genes in human islets
exposed to control or palmitate treatment. Data are presented as
mean ± sem. *P ≤0.05. T2D, type 2 diabetes.
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in DNA methylation might have a combined larger effect
which together could contribute to the pathogenesis of
the disease. In support of this hypothesis, previous studies
have shown relatively modest differences of DNA methy-
lation in non-cancerous tissues and cell types, ranging
from 0.13% to 11% [9,49,50]. However, even an absolute
change of only a few percent units can represent a large
difference in relative terms, as evident by the findings in
our study where the fold change of DNA methylation be-
tween the treatment groups (palmitate treatment/control
treatment) ranged from 0.54 to 1.84. This is in line with
data from a recent study, where we found differential
DNA methylation of 3,116 CpG sites in human pancreatic
islets from subjects with T2D compared with non-diabetic
controls with a fold change ranging from 0.58 to 1.61
when dividing the degree of methylation in diabetics with
that in controls [48].
We also identified many genes with a difference in
mRNA expression and a corresponding change in DNA
methylation. This could suggest that altered DNA methy-
lation influences the expression of the corresponding
genes. Indeed, we have previously shown that increasedDNA methylation reduces the transcriptional activity in
functional in vitro studies [5,8]. Interestingly, here we find
decreased expression in parallel with increased DNA
methylation of several candidate genes for T2D, such as
TCF7L2 and GLIS3 [51], in palmitate-treated human is-
lets, suggesting that lipid-induced epigenetic modifications
may affect the risk for diabetes. The fact that many of the
up-regulated genes have corresponding increased DNA
methylation could be due to the location of these CpG
sites in the gene body. Indeed, DNA methylation of the
gene body has been demonstrated to have a positive effect
on gene expression [52]. The gene regions with differential
gene expression but without any change in DNA methyla-
tion could be targets for other forms of transcriptional
regulation, such as histone modifications and/or altered
activation by transcription factors. Also, genetic and epi-
genetic variation may interact to affect gene expression
and subsequently contribute to the development of
complex metabolic disease, such as obesity and T2D. In-
deed, it has previously been shown that SNPs that
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can influence the expression of target genes by interfer-
ing with certain proteins [53]. Moreover, we recently
showed that approximately 50% of SNPs associated
with T2D are CpG-SNPs, which affect the degree of DNA
methylation in the SNP site as well as gene expression and
alternative splicing events in human pancreatic islets [7].
It has been hypothesized that since DNA methylation can
affect the regulation of splicing, CpG-SNPs can possibly
affect alternative splicing events [54].
There is an increased risk for obesity and T2D among
children with obese and/or diabetic parents [55,56]. Add-
itionally, rodent studies demonstrate that an altered intra-
uterine environment gives rise to epigenetic changes,
which later in life can predispose the offspring to impaired
metabolism and T2D [57-59]. These data suggest that epi-
genetic modifications contribute to the pathogenesis of
T2D. Based on the results from our study, we speculate
that early exposure to palmitate may affect the epigenetic
patterns of genes which are known to affect the risk
of T2D. This may increase the risk of disease later in
life. However, we cannot exclude that epigenetic changes
seen in patients with T2D are secondary to the disease
[4,5,48,60,61].
Our human insulin secretion data are in concordance
with previous rodent studies, where palmitate treatment
was found to lower glucose-stimulated insulin secretion in
rodent pancreatic islets [17,18]. A tight coupling of gly-
colysis to mitochondrial respiration and ATP production
is essential for proper beta-cell function and glucose-
stimulated insulin secretion. Palmitate treatment of hu-
man islets resulted in altered expression of individual
metabolic genes as well as of genes in metabolic pathways
such as glycolysis/gluconeogenesis, pyruvate metabolism
and biosynthesis of unsaturated fatty acids. Additionally,
several down-regulated genes in the enriched metabolic
pathways encode proteins which are part of the respira-
tory chain, for example, NDUFA4, NDUFB5, NDUFS1,
NDUFS2, SDHA and UQCRB. Decreased expression of
these genes may contribute to decreased oxidative phos-
phorylation and subsequently decreased ATP production
and insulin secretion in islets exposed to lipotoxicity. In-
deed, our previous study showed that decreased expres-
sion of genes involved in oxidative phosphorylation results
in impaired insulin secretion [62].
While some studies have found decreased beta-cell
number in T2D islets, others do not find an altered cell
composition in diabetic islets [10,63-65]. In the present
study, palmitate had no significant effect on apoptosis in
human islets and it is hence unlikely that the beta-cell
number is significantly decreased. As the majority of cell
types in human islets have important effects on whole
body glucose homeostasis [23], it is physiologically war-
ranted to study both whole human islets and cell-linesrepresenting the individual cell types in the pancreatic
islets.
Additionally, the insulin signaling pathway was signifi-
cantly enriched when performing a pathway analysis on
all the significant expression data, including both up-
and down-regulated genes. Interestingly, this pathway
was also enriched when performing a pathway analysis
on the differentially methylated genes. Previous studies
have shown that insulin signaling contributes in the
regulation of beta-cell mass and apoptosis as well as in-
sulin synthesis and secretion [66] and here we show that
this pathway is affected by palmitate treatment in human
islets. This in turn could potentially affect insulin secre-
tion in these islets. PPARGC1A (encoding PGC1α) is a
part of the insulin signaling pathway and its expression
was reduced in human islets exposed to palmitate. We
have previously shown that PPARGC1A expression is de-
creased in islets from T2D patients compared to non-
diabetics, and PPARGC1A expression correlated positively
with insulin secretion in human islets [6]. PPARGC1A
encodes a transcriptional co-activator of mitochondrial
genes involved in oxidative phosphorylation and silencing
of PPARGC1A in human islets results in decreased insulin
secretion [6]. Furthermore, SCD (encoding for stearoyl-
CoA desaturase (delta-9-desaturase)) was up-regulated in
human islets due to palmitate treatment. SCD is a compo-
nent of the biosynthesis of unsaturated fatty acids path-
way, which was enriched in the KEGG pathway analysis.
Stearoyl-CoA desaturase catalyzes the conversion of satu-
rated fatty acids to unsaturated fatty acids, and it has been
shown to protect rodent and human beta-cells from
palmitate-induced ER stress and apoptosis [67,68]. Our re-
sult is in accordance with these previous studies and could
provide an explanation for the absence of an increase in
apoptosis in the palmitate-treated human islets.
Furthermore, the “one carbon pool by folate” pathway
was enriched in the KEGG pathway analysis using both
mRNA expression data and DNA methylation data. Al-
tered expression of genes in this pathway may affect the
amount of methyl donors, for example, S-adenosyl me-
thionine in the islets exposed to palmitate and, thereby,
contribute to differential DNA methylation. SHMT2
and MTHFD2 were both up-regulated due to palmitate
exposure. The enzymes encoded by these genes are in-
volved in the folate cycle which is linked to the methionine
cycle, which in turn controls the amount of S-adenosyl
methionine [69].
Importantly, our study demonstrates that palmitate
directly affects the expression of genes that also show
differential expression in islets from diabetic donors
[70]. Additionally, some of our in vitro findings were val-
idated in a cohort of islets from donors with a large
spread in BMI (17.6 to 40.1 kg/m2) suggesting that lipid-
induced changes seen in vitro correspond to those
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impact of lipotoxicity on the expression of a limited
number of candidate genes in human islets in vitro
[24-26], the present study is to our knowledge the first
to perform a genome-wide analysis of gene expression in
lipotoxic-treated human islets of more than five donors
[28,29].
It is debated whether lipotoxicity can occur in the ab-
sence of high glucose levels, a phenomenon known as
glucolipotoxicity. However, previous in vivo studies in
humans have shown that prolonged exposure (24 to
48 h) to free fatty acids, in the absence of elevated glu-
cose levels, perturbs islet function [20]. Moreover, a re-
cent study showed that the lipotoxic effect of palmitate
occurs even at low concentrations of glucose in intact
human islets [30]. Our findings provide further evidence
that palmitate-induced lipotoxicity under normal glucose
conditions results in extensive transcriptional changes
and impaired insulin secretion in human islets. It is im-
portant, however, to note that our study only examined
the effects of palmitate on human islets, and it is known
that different fatty acids can have divergent, and even
opposite, effects on cell function. Also, the in vivo fatty
acid composition in plasma contains several different
fatty acids [71] where palmitate is one of the most abun-
dant saturated fatty acids. We can therefore in our study
not rule out that other types of fatty acids have add-
itional effects on human islets. However, our study pro-
vides evidence for palmitate-induced changes on gene
expression, DNA methylation and insulin secretion
which might be of relevance to phenotypes seen in obese
individuals and T2D patients. Finally, as our previous
studies have shown that the genome-wide methods used
in the present study are robust and reproducible, we did
not technically validate the array results in the present
study [8,72-74].Conclusion
In conclusion, we have identified novel genes and meta-
bolic pathways that are affected by palmitate exposure in
human pancreatic islets. Importantly, a number of these
genes also show differential gene expression in islets
from patients with T2D. We have also shown for the
first time that there are both global and specific changes
in the DNA methylation pattern in the palmitate-treated
islets which may affect mRNA expression. Together,
these changes may contribute to the impaired insulin se-
cretion seen in palmitate-treated human islets.Additional files
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